Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotech company, has reached a key milestone in its push to transform Parkinson’s treatment. The company finalized agreements for a private placement of common stock and pre-funded warrants, raising $15 million in gross proceeds. The first tranche will close on March 20, 2026. A second tranche of up to $15 million could follow by April 30, 2026. In addition, the deal includes 50% warrant coverage, which could bring in up to $33.3 million if exercised.
Meanwhile, Greg Bailey, M.D., is leading the transaction. He currently serves on the Board and will now step in as Co-Chairman. He brings deep experience in biotech investing and company building. Notably, he played key roles in Biohaven Ltd. and Medivation, both acquired by Pfizer for billions.
Strategic Financing to Propel Clinical Milestones
CEO Steve Ledger emphasized the importance of the raise. He pointed to the company’s progress, including dosing the first patient in its registrational trial and aligning with the FDA on a 505(b)(2) pathway. As a result, he said the financing positions Serina to reach its most important value-driving milestones. He also noted that the milestone-based structure ties funding to trial progress while preserving flexibility for additional capital.
At the same time, Dr. Bailey highlighted the broader potential. He explained that Serina’s POZ technology could improve both safety and pharmacokinetics for drugs limited by side effects. With clear FDA feedback supporting a capital-efficient path for SER-252, he believes the company is well positioned to advance treatment for advanced Parkinson’s patients.
Details of the Financing Agreement
Under the agreement, Serina will offer common stock at $2.25 per share. It will also issue pre-funded warrants at a similar price, minus a nominal $0.0001 exercise cost. Each share or warrant includes an additional warrant to purchase half a share at $5.00. These warrants carry a four-year term.
Moreover, the company can call the warrants under certain conditions. These include dosing the first patient in Cohort 2 of the SER-252 Phase 1b study or reaching September 30, 2026, if the stock trades above $10.00.
The first $15 million tranche should close shortly. The second depends on standard closing conditions. If investors fully exercise the first tranche warrants, Serina could raise another $16.7 million. In parallel, the company amended its September 2025 convertible note, removing obligations tied to future funding.
SER-252: A Promising Therapy for Advanced Parkinson’s Disease
SER-252 uses Serina’s proprietary POZ Platform™. It is an investigational apomorphine therapy designed to deliver continuous dopaminergic stimulation (CDS). This approach aims to reduce complications like dyskinesia, often caused by levodopa.
Unlike traditional options, SER-252 has shown in preclinical studies that it may deliver steady stimulation without causing skin reactions.
Currently, the Phase 1b registrational study is underway. Researchers are evaluating safety, tolerability, pharmacokinetics, and early efficacy. Initial dosing has already begun in Australia, and U.S. expansion is planned. An independent Safety Review Committee will guide dose escalation. The company expects to enter Cohort 2 by Q3 2026, with topline results anticipated in the first half of 2027.
The POZ Platform™: Transforming Drug Delivery
At the core of Serina’s approach is the POZ Platform™, based on poly(2-oxazoline), a synthetic, water-soluble polymer. This technology allows precise control over drug loading and release. As a result, it may help stabilize drug levels and improve safety, especially for therapies with narrow therapeutic windows.
Beyond neurology, the platform has broader applications. It could support oncology, rare diseases, RNA therapies, and antibody-drug conjugates. Therefore, Serina is exploring partnerships, co-development deals, and licensing opportunities. This includes its existing collaboration with Pfizer on lipid nanoparticle delivery.
Looking Ahead
With fresh capital and a clear regulatory path, Serina is moving forward with momentum. Its POZ Platform™ and SER-252 program highlight a focused effort to address unmet needs in advanced Parkinson’s disease while expanding into other therapeutic areas.
For more investor relations information on Serina Therapeutics, Inc. please visit www.investors.serinatx.com.
.
The post Serina Therapeutics Secures $15 Million in Private Placement to Advance Parkinson’s Therapy appeared first on PRISM MarketView.